Biosign Announces Application to List on the TSX-V

TORONTO, July 15 /CNW/ - Biosign Technologies Inc. (CNSX: BIO) ("Biosign") today announced it has made application to list its outstanding common shares on the TSX Venture Exchange. Currently, Biosign's common shares are traded on the Canadian National Stock Exchange (CNSX).

About Biosign Technologies Inc.

Biosign provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT(R) medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign please visit www.biosign.com

The CNSX has neither approved nor disapproved the contents of this press release.

%SEDAR: 00014068E

For further information: Radu Leca, President & CEO, Biosign Technologies Inc., Phone: [phone] ext. 234, Email: [email protected]